Phosphorylation of PED/PEA‑15 at Ser116 and phosphorylation of p27 at Thr187 indicates a poor prognosis in hepatocellular carcinoma

Wu,Yifeng; Li,Xianpeng; Chen,Mingliang; Liu,Zhikun; Zhang,Xuanyu; Zheng,Shusen; Xu,Xiao

doi:10.3892/ol.2021.12438

Phosphorylation of PED/PEA‑15 at Ser116 and phosphorylation of p27 at Thr187 indicates a poor prognosis in hepatocellular carcinoma

Authors:
- Yifeng Wu
- Xianpeng Li
- Mingliang Chen
- Zhikun Liu
- Xuanyu Zhang
- Shusen Zheng
- Xiao Xu
View Affiliations

Affiliations: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, P.R. China, Division of Hepatobiliary and Pancreatic Surgery, Yinzhou Hospital Affiliated to Medical School of Ningbo University, Ningbo, Zhejiang 315040, P.R. China
Published online on: January 6, 2021 https://doi.org/10.3892/ol.2021.12438
Article Number: 177
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) constitutes a deadly cancer with a high rate of recurrence and metastasis. Phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes‑15 (PED/PEA‑15) is a protein involved in the metabolism of glucose that regulates numerous cellular processes, including cell division, apoptosis and migration in numerous types of cancer. However, PED/PEA‑15 may act as a tumor‑promotor or a tumor‑suppressor depending on its phosphorylation status. In the present study, the association between the phosphorylation of PED/PEA‑15 at Ser116 [PED/PEA‑15(S116)], the phosphorylation of P27 at Thr187 [P‑p27(T187)] and the clinicopathological features and prognosis of patients with HCC was assessed. The levels of PED/PEA‑15(S116) and P‑p27(T187) were determined using immunohistochemistry and western blotting analysis in resected liver tumor tissues and adjacent non‑cancerous tissues obtained from 60 patients with HCC as well as normal liver tissues from 12 patients with benign lesions. The association between the expression levels of these two markers and the clinicopathological features of patients with HCC was explored. Using the Kaplan‑Meier method, the prognostic value of PED/PEA‑15(S116) and P‑p27(T187) expression levels was determined. The results demonstrated that the levels of PED/PEA‑15(S116) and P‑p27(T187) proteins were remarkably higher in the HCC group compared with those in the adjacent and normal tissue groups (both P<0.05). In addition, a moderate positive correlation was observed between the levels of PED/PEA‑15(S116) and P‑p27(T187) (r=0.434; P<0.05). The levels of these two proteins were associated with the Edmondson grade, Tumor‑Node‑Metastasis (TNM) stage, vascular invasion and tumor multiplicity (all P<0.05). Furthermore, the Kaplan‑Meier analysis results demonstrated that patients with HCC that presented with positive expression of PED/PEA‑15(S116) and P‑p27(T187) exhibited a dismal prognosis compared with that in patients with negative expression regarding the overall survival (OS), as well as disease‑free survival (both P<0.05). Multivariate Cox analysis revealed that the TNM stage (P<0.05), vascular invasion (P<0.05), PED/PEA‑15(S116) levels (P<0.001) and P‑p27(T187) levels (P<0.05) were independent prognostic factors for OS in patients with HCC. In conclusion the results of the present study demonstrated that PED/PEA‑15(S116) and P‑p27(T187) levels were upregulated in HCC tissues compared with those in the adjacent and normal tissues; PED/PEA‑15(S116) and P‑p27(T187) expression may serve as an indicator of a poor prognosis in patients with HCC, suggesting that these proteins may be prospective therapeutic targets for HCC.

View Figures

View References

1	Mittal S and El-Serag HB: Epidemiology of hepatocellular carcinoma: Consider the population. J Clin Gastroenterol. 47 (Suppl):S2–S6. 2013. View Article : Google Scholar : PubMed/NCBI
2	Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M and Negri E: Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 67:302–309. 2017. View Article : Google Scholar : PubMed/NCBI
3	Singal AG and El-Serag HB: Hepatocellular carcinoma from epidemiology to prevention: Translating knowledge into practice. Clin Gastroenterol Hepatol. 13:2140–2151. 2015. View Article : Google Scholar : PubMed/NCBI
4	Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M and Sherman M: Gores: Hepatocellular carcinoma. Nat Rev Dis Primers. 2:160182016. View Article : Google Scholar : PubMed/NCBI
5	Cai SH, Lu SX, Liu LL, Zhang CZ and Yun JP: Increased expression of hepatocyte nuclear factor 4 alpha transcribed by promoter 2 indicates a poor prognosis in hepatocellular carcinoma. Therap Adv Gastroenterol. 10:761–771. 2017. View Article : Google Scholar : PubMed/NCBI
6	Wong SS, Kim KM, Ting JC, Yu K, Fu J, Liu S, Cristescu R, Nebozhyn M, Gong L, Yue YG, et al: Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing. Nat Commun. 5:54772014. View Article : Google Scholar : PubMed/NCBI
7	Danziger N, Yokoyama M, Jay T, Cordier J, Glowinski J and Chneiweiss H: Cellular expression, developmental regulation, and phylogenic conservation of PEA-15, the astrocytic major phosphoprotein and protein kinase C substrate. J Neurochem. 64:1016–1025. 1995. View Article : Google Scholar : PubMed/NCBI
8	Greig FH and Nixon GF: Phosphoprotein enriched in astrocytes (PEA)-15: A potential therapeutic target in multiple disease states. Pharmacol Ther. 143:265–274. 2014. View Article : Google Scholar : PubMed/NCBI
9	Quintavalle C, Di Costanzo S, Zanca C, Tasset I, Fraldi A, Incoronato M, Mirabelli P, Monti M, Ballabio A, Pucci P, et al: Phosphorylation-regulated degradation of the tumor-suppressor form of PED by chaperone-mediated autophagy in lung cancer cells. J Cell Physiol. 229:1359–1368. 2014. View Article : Google Scholar : PubMed/NCBI
10	Xie X, Tang H, Pengliu, Kong Y, Wu M, Xiao X, Yang L, Gao J, Wei W, Lee J, et al: Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer. Cancer Lett. 356:374–381. 2015. View Article : Google Scholar : PubMed/NCBI
11	Crespo-Flores SL, Cabezas A, Hassan S and Wei Y: PEA-15 C-terminal tail allosterically modulates death-effector domain conformation and facilitates protein-protein interactions. Int J Mol Sci. 20:33352019. View Article : Google Scholar
12	Mace PD, Wallez Y, Egger MF, Dobaczewska MK, Robinson H, Pasquale EB and Riedl SJ: Structure of ERK2 bound to PEA-15 reveals a mechanism for rapid release of activated MAPK. Nat Commun. 4:16812013. View Article : Google Scholar : PubMed/NCBI
13	Fiory F, Formisano P, Perruolo G and Beguinot F: Frontiers: PED/PEA-15, a multifunctional protein controlling cell survival and glucose metabolism. Am J Physiol Endocrinol Metab. 297:E592–E601. 2009. View Article : Google Scholar : PubMed/NCBI
14	Besson A, Dowdy SF and Roberts JM: CDK inhibitors: Cell cycle regulators and beyond. Dev Cell. 14:159–169. 2008. View Article : Google Scholar : PubMed/NCBI
15	Bencivenga D, Caldarelli I, Stampone E, Mancini FP, Balestrieri ML, Della Ragione F and Borriello A: p27(Kip1) and human cancers: A reappraisal of a still enigmatic protein. Cancer Lett. 403:354–365. 2017. View Article : Google Scholar : PubMed/NCBI
16	Gupta A, Saltarski JM, White MA, Scaglioni PP and Gerber DE: Therapeutic targeting of nuclear export inhibition in lung cancer. J Thorac Oncol. 12:1446–1450. 2017. View Article : Google Scholar : PubMed/NCBI
17	Peng M, Wang J, Zhang D, Jin H, Li J, Wu XR and Huang C: PHLPP2 stabilization by p27 mediates its inhibition of bladder cancer invasion by promoting autophagic degradation of MMP2 protein. Oncogene. 37:5735–5748. 2018. View Article : Google Scholar : PubMed/NCBI
18	He W, Wang X, Chen L and Guan X: A crosstalk imbalance between p27(Kip1) and its interacting molecules enhances breast carcinogenesis. Cancer Biother Radiopharm. 27:399–402. 2012. View Article : Google Scholar : PubMed/NCBI
19	Grimmler M, Wang Y, Mund T, Cilensek Z, Keidel EM, Waddell MB, Jäkel H, Kullmann M, Kriwacki RW and Hengst L: Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. Cell. 128:269–280. 2007. View Article : Google Scholar : PubMed/NCBI
20	Gallastegui E, Bicer A, Orlando S, Besson A, Pujol MJ and Bachs O: p27(Kip1) represses the Pitx2-mediated expression of p21(Cip1) and regulates DNA replication during cell cycle progression. Oncogene. 36:350–361. 2017. View Article : Google Scholar : PubMed/NCBI
21	Kim JE and Kang TC: Nucleocytoplasmic p27(Kip1) export is required for ERK1/2-mediated reactive astroglial proliferation following status epilepticus. Front Cell Neurosci. 12:1522018. View Article : Google Scholar : PubMed/NCBI
22	Zhou L, Rui JA, Ye DX, Wang SB, Chen SG and Qu Q: Edmondson-Steiner grading increases the predictive efficiency of TNM staging for long-term survival of patients with hepatocellular carcinoma after curative resection. World J Surg. 32:1748–1756. 2008. View Article : Google Scholar : PubMed/NCBI
23	Wang GK, Li SH, Zhao ZM, Liu SX, Zhang GX, Yang F, Wang Y, Wu F, Zhao XX and Xu ZY: Inhibition of heat shock protein 90 improves pulmonary arteriole remodeling in pulmonary arterial hypertension. Oncotarget. 7:54263–54273. 2016. View Article : Google Scholar : PubMed/NCBI
24	Andreozzi M, Quintavalle C, Benz D, Quagliata L, Matter M, Calabrese D, Tosti N, Ruiz C, Trapani F, Tornillo L, et al: HMGA1 expression in human hepatocellular carcinoma correlates with poor prognosis and promotes tumor growth and migration in in vitro models. Neoplasia. 18:724–731. 2016. View Article : Google Scholar : PubMed/NCBI
25	Chen SL, Liu LL, Lu SX, Luo RZ, Wang CH, Wang H, Cai SH, Yang X, Xie D, Zhang CZ and Yun JP: HBx-mediated decrease of AIM2 contributes to hepatocellular carcinoma metastasis. Mol Oncol. 11:1225–1240. 2017. View Article : Google Scholar : PubMed/NCBI
26	Morofuji N, Ojima H, Hiraoka N, Okusaka T, Esaki M, Nara S, Shimada K, Kishi Y and Kondo T: Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma. Clin Proteomics. 13:282016. View Article : Google Scholar : PubMed/NCBI
27	Jiang X, Zhang C, Li W, Jiang D, Wei Z, Lv M, Xie X and Sun X: PEA-15 contributes to the clinicopathology and AKT-regulated cisplatin resistance in gastric cancer. Oncol Rep. 41:1949–1959. 2019.PubMed/NCBI
28	Fiory F, Parrillo L, Raciti GA, Zatterale F, Nigro C, Mirra P, Falco R, Ulianich L, Di Jeso B, Formisano P, et al: PED/PEA-15 inhibits hydrogen peroxide-induced apoptosis in Ins-1E pancreatic beta-cells via PLD-1. PLoS One. 9:e1136552014. View Article : Google Scholar : PubMed/NCBI
29	Mohammed HN, Pickard MR and Mourtada-Maarabouni M: The protein phosphatase 4 - PEA15 axis regulates the survival of breast cancer cells. Cell Signal. 28:1389–1400. 2016. View Article : Google Scholar : PubMed/NCBI
30	Bartholomeusz C, Rosen D, Wei C, Kazansky A, Yamasaki F, Takahashi T, Itamochi H, Kondo S, Liu J and Ueno NT: PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival. Cancer Res. 68:9302–9310. 2008. View Article : Google Scholar : PubMed/NCBI
31	Lee J, Bartholomeusz C, Krishnamurthy S, Liu P, Saso H, Lafortune TA, Hortobagyi GN and Ueno NT: PEA-15 unphosphorylated at both serine 104 and serine 116 inhibits ovarian cancer cell tumorigenicity and progression through blocking β-catenin. Oncogenesis. 1:e222012. View Article : Google Scholar : PubMed/NCBI
32	Weijman JF, Riedl SJ and Mace PD: Structural studies of ERK2 protein complexes. Methods Mol Biol. 1487:53–63. 2017. View Article : Google Scholar : PubMed/NCBI
33	Quintavalle C, Hindupur SK, Quagliata L, Pallante P, Nigro C, Condorelli G, Andersen JB, Tagscherer KE, Roth W, Beguinot F, et al: Phosphoprotein enriched in diabetes (PED/PEA15) promotes migration in hepatocellular carcinoma and confers resistance to sorafenib. Cell Death Dis. 8:e31382017. View Article : Google Scholar : PubMed/NCBI
34	Hoellein A, Graf S, Bassermann F, Schoeffmann S, Platz U, Holzlwimmer G, Kröger M, Peschel C, Oostendorp R, Quintanilla-Fend L and Keller U: Cks1 promotion of S phase entry and proliferation is independent of p27Kip1 suppression. Mol Cell Biol. 32:2416–2427. 2012. View Article : Google Scholar : PubMed/NCBI
35	Pippa R, Espinosa L, Gundem G, Garcia-Escudero R, Dominguez A, Orlando S, Gallastegui E, Saiz C, Besson A, Pujol MJ, et al: p27Kip1 represses transcription by direct interaction with p130/E2F4 at the promoters of target genes. Oncogene. 31:4207–4220. 2012. View Article : Google Scholar : PubMed/NCBI
36	Besson A, Assoian RK and Roberts JM: Regulation of the cytoskeleton: An oncogenic function for CDK inhibitors? Nat Rev Cancer. 4:948–955. 2004. View Article : Google Scholar : PubMed/NCBI
37	Besson A, Gurian-West M, Schmidt A, Hall A and Roberts JM: p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev. 18:862–876. 2004. View Article : Google Scholar : PubMed/NCBI
38	Shin M, Lee KE, Yang EG, Jeon H and Song HK: PEA-15 facilitates EGFR dephosphorylation via ERK sequestration at increased ER-PM contacts in TNBC cells. FEBS Lett. 589:1033–1039. 2015. View Article : Google Scholar : PubMed/NCBI